Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Phase 3 Completed 2639 enrolled Takeda

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.

Timeline

Start: 2009-03
Primary completion: 2012-10
Completion: 2012-10

Publications

Gordon J, McEwan P, Hurst M, Puelles J. The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Ther. 2016 Dec;7(4):825-845. doi: 10.1007/s13300-016-0206-7. Epub 2016 Oct 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alogliptin	Unknown	12.5 mg	Oral
Subject	Alogliptin	Unknown	25 mg	Oral
Comparator	Glipizide	Small molecule	5 mg	Oral
Comparator	Glipizide	Small molecule	20 mg	Oral
Background	Metformin	Small molecule	1500 mg	Oral
Background	Metformin	Small molecule	3300 mg	Oral

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Publications

Drugs

Indications